Skip to content
How Humanized mice studies can accelerate preclinical research in infectious diseases

Event Information:


April 25, 2023


Related Models

CD34+ Humanized Mouse

How Humanized Mice Studies Can Accelerate Preclinical Research in Infectious Diseases

The World Health Organization has reported that HIV and malaria continue to be significant public health issues around the world in 2021, with 2.3 million people living with HIV infected and 247 million malaria cases worldwide.

In response to these challenges, TransCure bioServices and The Art of Discovery are presenting a webinar to discuss the potential use of Humanized mice models in developing treatments for these infections.

In the first part, Dr. Sebastien Tabruyn, PhD, TransCure bioServices, will discuss how the human immune system responds to infection in a Humanized CD34-NCG mouse model. He will also discuss the preclinical analysis toolkit of the HIV platform, and how the Humanized mouse model allows for the evaluation of drug candidates, for infectious diseases. TransCure bioServices offers preclinical contract research services, including unique mouse modeling with functional Humanized systems, to provide predictive in vivo pharmacology testing in the field of immuno-oncology, inflammation, autoimmune diseases, infectious diseases, and vaccine development. Their unparalleled expertise, powerful Humanized mouse models, short lead times, and flexibility support clients from study design to final report.

In the second part of the webinar, Dr. Iñigo Angulo-Barturen, PhD, The Art of Discovery (TAD), will discuss the use of Humanized Plasmodium falciparum mouse models in the study of human malaria and the in vivo evaluation of new antimalarial drugs. He will present the characteristics of the Humanized P. falciparum asexual blood stage (ABS) mouse models available at TAD and how they can be used to study the development of resistance during suboptimal treatment regimens. He will also discuss the efficacy of monoclonal antibodies and drugs against susceptible and resistant strains.

The Art of Discovery specializes in preclinical pharmacokinetic and pharmacodynamic (PK/PD) evaluation of new medicines, with an extensive experience in developing standardized mice models for cancer, inflammation, and infectious diseases, including the asexual erythrocyte and liver stages of Plasmodium falciparum in non-myelodepleted Humanized mice (Pfalc HuMouse model). TAD collaborates with funding agencies, pharmaceutical companies, and researchers from academic institutions to contribute to the development of new antimalarial treatments for people in need. They provide industrial-quality Humanized mouse models of human malaria to address translational pharmacology and basic scientific questions by pharmaceutical companies and research groups.

Sebastien Tabruyn, PhD, Chief Scientific OfficerPresenting for TransCure bioServices:

Sebastien Tabruyn, PhD, Chief Scientific Officer

Chief Scientific Officer and General Manager. Sebastien Tabruyn holds a PhD in Molecular Biology from the University of Liege (Belgium). After 20 years of experience as Project leader in renowned international academic research institutes including UCSF (California, USA), the Centre for Cancer Biology (Adelaide, Australia) and the University of Maastricht (Netherlands), he joined TransCure bioServices in 2013 to develop the first IO Humanized mouse models. Sebastien Tabruyn published more than 30 peer-reviewed publications mostly focused on oncology, inflammation, immunity, and angiogenesis.

Iñigo Angulo-Barturen, PhD, CEOPresenting for The Art of Discovery:

Iñigo Angulo-Barturen, PhD, CEO

Dr. Angulo-Barturen has a degree in Biology from the University of the Basque Country (Leioa, Spain), a PhD in Immunology from the Universidad Complutense (Madrid, Spain) and is specialist in Immunology (residency at Hospital Universitario San Carlos, Madrid, Spain). After a post-doctoral period developing new immunotherapies for fungal infections in immunodepressed patients (Centro de Biología Molecular, Cantoblanco, Spain and GlaxoWellcome, Tres Cantos, Madrid), he led the preclinical Therapeutic Efficacy Group at GlaxoSmithKline, Tres Cantos, Spain), conducting the evaluation of new medicines in drug discovery programs for Malaria and Tuberculosis. At GSK, Dr. Angulo-Barturen developed the first industrial murine model of P. falciparum human malaria that became the gold standard in drug discovery for translational research in programs supported by the Medicines for Malaria Venture. In 2015, Dr. Angulo-Barturen founded The Art of Discovery, a company specialized in translational evaluation of new drugs in Humanized mouse models of key human diseases.